# Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study

> **NCT05294289** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 77 (actual)

## Conditions studied

- PIK3CA-related Overgrowth Spectrum

## Interventions

- **OTHER:** Alpelisib

## Key facts

- **NCT ID:** NCT05294289
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-16
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-06-28
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05294289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05294289, "Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05294289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*